- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Hypha Labs, Inc.: Hypha Labs Highlights Parallels Between Emerging Psychedelic Industry and Early Cannabis Market Expansion | 175 | ACCESS Newswire | State-Level Reform, Growing Public Acceptance, and Expanding Market Capitalizations Signal Potential Long-Term Industry Opportunity LAS VEGAS, NV / ACCESS Newswire / June 4, 2026 / Hypha Labs, Inc.... ► Artikel lesen | |
| 15.05. | Hypha Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 27.04. | Hypha Labs, Inc.: Trump Psychedelic Executive Order Accelerates Industry Growth | 319 | ACCESS Newswire | Hypha Labs, Inc. (FUNI) Positioned to Lead with AI-Driven Production Technology LAS VEGAS, NV / ACCESS Newswire / April 27, 2026 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology innovator focused on... ► Artikel lesen | |
| 09.04. | Hypha Labs, Inc. Announces Partnership with Mycology Resources, LLC | 397 | ACCESS Newswire | Companies Combine Technology, Cultivation, and Global Distribution LAS VEGAS, NV / ACCESS Newswire / April 9, 2026 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology innovator in the functional mushroom... ► Artikel lesen | |
| 30.01. | Hypha Labs, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| HYPHA LABS Aktie jetzt für 0€ handeln | |||||
| 15.01. | Hypha Labs, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 30.12.25 | Hypha Labs, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 01.10.25 | Hypha Labs, Inc.: Hypha Labs and Tryptomics Launch Phase II of Strategic Partnership, Pairing Patented Mushroom Accelerator with World-Class Internal Quality Control & Fungal Genomics | 552 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / October 1, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology company pioneering the development of functional mushroom technologies, today announced the official... ► Artikel lesen | |
| 29.09.25 | Hypha Labs, Inc.: Hypha Labs and Automated Technical Services Enter into Agreement to Scale its Mushroom Accelerator Technology for Commercial Nutraceutical Manufacturing | 318 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / September 29, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology company pioneering the development of functional mushroom technologies, announced today that it... ► Artikel lesen | |
| 11.08.25 | Hypha Labs, Inc.: Hypha Labs Expands List of Functional Mushrooms Able to be Produced in its Revolutionary Mushroom Accelerator | 321 | ACCESS Newswire | Simple, In-Home Eight Day Cycle Generates Significant Yields of The World's Most Popular Mushroom Strains LAS VEGAS, NV / ACCESS Newswire / August 11, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), an A.I. powered... ► Artikel lesen | |
| 28.07.25 | Hypha Labs, Inc.: Hypha Labs Provides Shareholder Update | 845 | ACCESS Newswire | LAS VEGAS, NEVADA / ACCESS Newswire / July 28, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), an Artificial Intelligence (AI) powered pioneer in functional mushroom sciences and the creator of the MicroPearls... ► Artikel lesen | |
| 10.06.25 | Hypha Labs, Inc.: Hypha Labs Files New Patent Application for Its Suite of Artificial Intelligence Techniques for Its Mushroom Accelerator | 568 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / June 10, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), an Artificial Intelligence (AI) powered pioneer in functional mushroom sciences and the creator of the MicroPearls suite... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 254,00 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 35,590 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| JADE BIOSCIENCES | 16,940 | 0,00 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen | |
| QIAGEN | 31,920 | -2,18 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Feedback aus Gesprächen mit etlichen US-Laborexperten deute darauf hin, dass... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 86,86 | -0,07 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| ADMA BIOLOGICS | 7,970 | 0,00 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 14,755 | -0,10 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| ERASCA | 11,970 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,315 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,720 | +0,13 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 59,28 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,520 | 0,00 % | Relay Therapeutics Shares Jump 18% | ||
| BEAM THERAPEUTICS | 29,370 | -0,10 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,190 | -0,15 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BIOCARDIA | 1,070 | +3,88 % | BioCardia Shares Surge 48% After FDA Feedback Supports Potential CardiAMP Approval Pathway |
HYPHA LABS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HYPHA LABS INC finden Sie auf Wallstreet Online.